Indication
Gluvan is indicated for the treatment of type 2 diabetes mellitus.
•As monotherapy.
•In dual combination with Metformin, a Sulfonylurea, a Thiazolidinedione or Insulin when diet, exercise and a single antidiabetic agent do not result in adequate glycemic control.
Dosage & Administration
Gluvan can be administered with or without food.
As monotherapy and in dual combination with Metformin, a Thiazolidinedione or Insulin: 50 mg or 100 mg daily. The 50 mg dose should be administered once daily in the morning and the 100 mg dose should be administered as two divided doses of 50 mg in the morning and evening.
In combination with a Sulfonylurea: 50 mg once daily administered in the morning.
Dosage in renal impairment: No dose adjustment is required in patients with mild renal impairment (creatinine clearance >50 ml/min). Not recommended in patients with moderate or severe renal impairment or in hemodialysis patients with end-stage liver disease.
Dosage in hepatic impairment: Should not be used in patients with hepatic impairment.
Contraindications
Contraindicated in patients with known hypersensitivity to Vildagliptin or any of the excipients.
Side effects
The most common side effects are nausea, peripheral edema, headache, tremor, asthenia and dizziness.
Drug interaction
Vildagliptin has a low potential for drug interactions. Vildagliptin is not a cytochrome P450 enzyme substrate and it does not inhibit or induce cytochrome P450 enzymes. So it is not likely to interact with co-medications that are substrates, inhibitors or inducers of these enzymes. No clinically relevant interactions with other oral antidiabetics (Glibenclamide, Pioglitazone, Metformin), Amlodipine, Digoxin, Ramipril, Simvastatin, Valsartan or Warfarin were observed after co-administration with Vildagliptin.
Reviews
There are no reviews yet.